THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING
Globe Editorial

Biotech bills give drugmakers too many years of exclusivity

November 24, 2009

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size +

The Biotech industry is vital to Massachusetts and deserves robust protection of its intellectual property. But the long-awaited bills emerging from the House and Senate give too many years of exclusivity to the original makers of biotech drugs -- 12 instead of five for regular drugs -- and serve to drive up healthcare costs. A compromise is in order. (Full article: 495 words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

  • $9.95 1 month archives pass
  • $24.95 3 months archives pass
  • $74.95 1 year archives pass